Vertex Pharmaceuticals Heading $600? A Stock Outlook
Investors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
This article compares expense ratios for SP 500 ETFs and index funds inside a Roth IRA, highlighting how fees affect long-term growth.
28,234 articlesInvestors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
Hydrogen policy momentum and rising costs are shaping a wide range of outcomes for plug power (plug) stock, with anal...
Delek US shares jumped as crude and refining margins strengthened. This article breaks down the drivers, the risks, a...
Robinhood just announced a substantial $1.5 billion buyback. In this analysis, we weigh the potential benefits agains...
A sharp, fear-driven decline hit Microsoft, but a deeper look suggests the selloff may reflect sentiment more than so...
Citigroup stands out as the bank watchers' proxy on a rare earnings day for the big five. Markets look for signs on l...
Analysts highlight three candidates with durable networks and real use cases, exploring chances for outsized gains by...
Fidelity Investments’ leadership, led by Abby Johnson, has quietly built a decades-long crypto program that critics n...
Jamie Dimon just turned 70, and a brush with a life-threatening health crisis years ago reshaped his view of success,...
Freshworks CEO Dennis Woodside has forged one of Silicon Valley’s most varied careers by tackling high-stakes challen...
Famed investor Michael Burry considered betting against SpaceX after its IPO but ultimately stayed neutral. The stock...
As the three-year mark of the Ripple-SEC ruling arrives, XRP has moved from regulator target to institutional asset, ...